| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2019: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2018: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2017: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Outline of Final Research Achievements |
Both lung cancer and interstitial pneumonia are refractory and highly comorbid diseases. In the present study, we identified miR-X of microRNA (miRNA) that commonly suppressed the mechanism underlying the development and progression of both diseases.
Using comprehensive miRNA expression analysis, we found commonly decreased expression levels of miR-X in lung cancer and interstitial pneumonia tissues in patients with comorbid lung cancer and interstitial pneumonia, compared to those in healthy lung and lung cancer tissues in patients with lung cancer without interstitial pneumonia. Overexpression of miR-X suppressed cell growth and epithelial-mesenchymal transition involved in cancer metastasis and invasion in lung cancer cell lines and inhibited differentiation of fibroblasts to myofibroblasts as an indicator of pulmonary fibrogenesis. These findings shown in in vitro assays were confirmed in in vivo assays using disease model mice.
|
